ViroCoreAI is Virovance’s proprietary AI engine for discovering new cancer drugs. It uses advanced machine learning and molecular modeling to design, rank, and optimize small molecules targeting cancer-driving proteins like CDK2.
Rapid identification of novel small molecules from vast chemical libraries using deep learning, molecular docking, and structure-based modeling.
We leverage structural biology and computational chemistry to design and prioritize molecules with strong binding affinity and drug-like properties.
Explore single or multiple oncology targets without being locked into a fixed discovery path—our tools adapt to our therapeutic vision.
All hits are ranked based on in silico predictions of pharmacokinetics, toxicity, solubility, and Lipinski’s Rule compliance.
Iterative optimization strategies guide you from promising hits to development-ready leads—tailored to your budget and timeline.
For media inquiries, partnership opportunities, or to learn more about our work, please use the form below to get in touch.
